PUBLISHER: IMARC | PRODUCT CODE: 1819937
PUBLISHER: IMARC | PRODUCT CODE: 1819937
The global animal model market size reached USD 1,916 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,151 Million by 2033, exhibiting a growth rate (CAGR) of 5.7% during 2025-2033.
Animal models are living, non-human species used in medical research and investigations. They are frequently selected due to their vast similarities with the genetics, anatomy, and physiology of humans. They assist in obtaining information about the prevention, diagnosis, and treatment of diseases without causing harm to a human. Some of the commonly utilized animal models include rodents, rats, mice, gerbils, guinea pigs, and hamsters. At present, they are widely preferred on account of their availability, ease of handling, and relatively low cost of use.
Presently, there is a continuous increase in the need for personalized medicines across the globe. This, in confluence with a rising prevalence of genetic disorders, such as down syndrome, Crohn's disease, breast cancer, and hemophilia, represents one of the key factors positively influencing the utilization of animal models in the pre-clinical development of drugs by researchers. Apart from this, they are also being utilized in biomedical research, toxicology, physiology, cancer research, neurological research, genetic research, and xenotransplantation around the world. Furthermore, the market is propelled by numerous technological advancements, such as the introduction of CRISPR-Cas9, a genome editing technology, which aids in reducing the time and cost required for enabling the production of animal models with extensive genetic modifications. This technology finds wide applicability in a variety of animals, ranging from early-branching metazoans to primates. Besides this, the sudden outbreak of the contagious coronavirus disease (COVID-19) pandemic is creating a favorable outlook for the market. This can be accredited to the increasing investments by international organizations like World Health Organization (WHO) and government authorities in research and development (R&D) activities to introduce vaccines and antiviral drugs.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Biocytogen, Charles River Laboratories International Inc, Envigo, Eurofins Scientific SE, GenOway S.A., Hera BioLabs, JSR Corporation, Ozgene Pty Ltd., PerkinElmer Inc., Taconic Biosciences Inc., The Jackson Laboratory and Trans Genic Inc.